Clinical Trials Logo
  1. Home
  2. Cancer of the Prostate
  3. NCT02578940

Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer — FALCON  

Cancer of the Prostate Clinical Trial

Official title:
A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment

Clinical Trial Summary

The main aim is to assess the impact of using 18F-fluciclovine (as a PET imaging radiotracer) on the clinical and treatment decision required for managing patients with biochemically recurrent prostate cancer (BCR) who are being considered for salvage treatment with the intention of providing disease cure. Also, this study will consolidate the information regarding diagnostic performance of fluciclovine PET/CT in a large number of prospectively followed patients at several centres in the UK and assess the effect of PSA level on the likelihood of detecting cancer lesions by 18F-fluciclovine

Clinical Trial Description

Proposed Research In the setting of growing single-centre evidence of superior diagnostic performance of 18F-fluciclovine PET/CT in BCR, our primary aim is to assess its clinical impact on treatment decisions in a multi-centre study in patients with BCR being considered for radical salvage treatment (with curative intent). In addition, we aim to further characterise its diagnostic performance, afforded by larger numbers of patients from multi-centre recruitment. We also aim to assess the effect of PSA level on probability of lesion detection by 18F-fluciclovine. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02578940
Study type Interventional
Source Blue Earth Diagnostics
Contact
Status Completed
Phase Phase 3
Start date November 2015
Completion date June 22, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Not yet recruiting NCT06363266 - A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers N/A
Active, not recruiting NCT02003924 - Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Phase 3
Completed NCT00643617 - CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry N/A
Completed NCT00844792 - Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer Phase 2
Completed NCT01303705 - Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Phase 1
Completed NCT04057859 - PCa Patients Managed With ADT to Examine the Effect of Nutritional Guidance and Aerobic/Resistance Fitness Training
Completed NCT00564928 - A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer Phase 2
Completed NCT02958787 - Vessel Sparing Prostate Radiation Therapy Phase 2
Completed NCT01897207 - Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer Phase 1/Phase 2
Recruiting NCT05241236 - MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
Active, not recruiting NCT03939689 - Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone Phase 2
Completed NCT02274350 - The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects N/A
Completed NCT00744549 - Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance Phase 2
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02212548 - Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose N/A
Completed NCT04017325 - European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up
Active, not recruiting NCT03238170 - MR-simulation in Radiotherapy for Prostate Cancer N/A